| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Net income | -24.4 | -26.3 |
| EPS (diluted, $ a share) | $-0.39 | $-0.43 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
10-Q filed with the SEC, NASDAQ: PLRX. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Pliant Therapeutics, Inc.: key numbers
- Share price
- $0.6932Close, Nov 16
- Market cap
- $43M
- Shares outstanding
- 61.99MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Pliant Therapeutics, Inc.
All →Pliant Therapeutics Financial Results
Pliant Therapeutics reported third quarter 2026 financial results and provided a corporate update, highlighting strong enrollment in its Phase 1b FORTIFY trial for PLN-101095. The company ended the quarter with $388.5 million in cash and equivalents, providing a projected cash runway into 2027. Key operational milestones included preclinical data for its integrin-mediated drug delivery platform and leadership appointments in medical and research roles.
- Term
- Q3 2026
“The third quarter reflected continued strong execution across the Organization, including robust FORTIFY enrollment and compelling proof-of-concept data generated from our integrin-mediated drug delivery platform.”
Bernard Coulie, M.D., Ph.D., President and Chief Executive Officer of Pliant